Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Yuya Seko,1 Taichiro Nishikawa,1 Atsushi Umemura,1 Kanji Yamaguchi,1 Michihisa Moriguchi,1 Kohichiroh Yasui,1 Mayumi Kimura,2 Hiroaki Iijima,3 Toshio Hashimoto,3 Yoshio Sumida,4 Takeshi Okanoue,5 Yoshito Itoh1 1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine,...

Full description

Bibliographic Details
Main Authors:	Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-11-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	canagliflozin Japanese NASH fibrosis stages SGLT2 inhibitor type 2 diabetes mellitus
Online Access:	https://www.dovepress.com/efficacy-and-safety-of-canagliflozin-in-type-2-diabetes-mellitus-patie-peer-reviewed-article-DMSO

Similar Items

Canagliflozin review – safety and efficacy profile in patients with T2DM
by: Jakher H, et al.
Published: (2019-02-01)

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats
by: Manal M.G. Mourad*, et al.
Published: (2023-07-01)

Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway
by: Mohamed S. Dabour, et al.
Published: (2023-08-01)

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
by: Messana JA, et al.
Published: (2017-02-01)

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
by: Juan J. Gorgojo-Martínez, et al.
Published: (2020-07-01)

Case Report: Post-gastrectomy reactive hyperinsulinemic hypoglicaemia: glucose trends before and after canagliflozin treatment
by: G. Bellastella, et al.
Published: (2023-08-01)

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
by: Νarjes Nasiri-Ansari, et al.
Published: (2018-07-01)

Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study
by: Juan J. Gorgojo-Martinez, et al.
Published: (2022-09-01)

Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension
by: Xiaojun Chen, et al.
Published: (2024-05-01)

Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
by: Juan J. Gorgojo-Martinez, et al.
Published: (2023-06-01)

SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia
by: Ching-Tien Lee, et al.
Published: (2023-12-01)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
by: Taha Sen, et al.
Published: (2021-12-01)

The role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolution
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01)

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
by: Masafumi Fukuda, et al.
Published: (2020-01-01)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease
by: Gabriela Dumitrita Stanciu, et al.
Published: (2023-11-01)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
by: Robert A. Fletcher, et al.
Published: (2023-07-01)

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2017-01-01)

Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice
by: Peiyang Song, et al.
Published: (2022-12-01)

Canagliflozin Ameliorates Oxidative Stress and Autistic-like Features in Valproic-Acid-Induced Autism in Rats: Comparison with Aripiprazole Action
by: Mohammed Moutaz Nakhal, et al.
Published: (2023-05-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
by: Ryo Goto, et al.
Published: (2019-04-01)

Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails
by: O. Y. Sukhareva, et al.
Published: (2022-02-01)

Cardiac dysfunction in a cohort of biopsy proven nonalcoholic steatohepatitis in comparison to nonalcoholic fatty liver
by: Jijo Varghese, et al.
Published: (2023-01-01)

Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
by: Nikolaos Perakakis, et al.
Published: (2021-06-01)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
by: Takahara M, et al.
Published: (2020-11-01)

Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study
by: Sammar Fathy Elhabal, et al.
Published: (2023-12-01)

Inhibition of sodium‐glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis‐related kidney disease
by: Takuro Nagoya, et al.
Published: (2019-12-01)

Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism
by: Elmar Zügner, et al.
Published: (2022-07-01)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023-02-01)

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus
by: Rong Qiu, MD, PhD, et al.
Published: (2014-06-01)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
by: Aaron Y. Kluger, et al.
Published: (2019-08-01)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
by: Chang Hee Jung, et al.
Published: (2014-08-01)

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
by: Abhinav Sharma, et al.
Published: (2024-02-01)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
by: Takashi Wada, et al.
Published: (2022-01-01)

Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression
by: Kannan Sridharan, et al.
Published: (2024-03-01)

SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
by: Mieczysław Dutka, et al.
Published: (2022-11-01)